NEW technology launched in the Capital to measure the field of vision in children and vulnerable people could be used to monitor and manage brain tumours, according to researchers.
The technology, known as saccadic vector optokinetic perimetry, is being developed by a new company called i2eye Diagnostics.
Current testing devices depend on a patient’s complete co-operation and involves keeping the head still, staring at a fixed point for several minutes.
The new device, which uses the patient’s natural reactions to movement and light to analyse their visual field, will allow them to move their head and will not require their feedback.
It means patients whose visual field was previously impossible to examine will have the test for the first time.
Peter Estibeiro, i2eye’s chief executive, said: “Our instrument is a generation ahead of anything else on the market.
“One of its first applications is in the monitoring and clinical management of children with brain tumours, where it can aid the decision-making process potentially leading to a better outcome.”